IRLAB Therapeutics AB Class A (6IRA) Income Statement
IRLAB Therapeutics AB Class A Income Statement
Last quarter (Q2 2026), IRLAB Therapeutics AB Class A's total revenue was $6.40M, a decrease of 67.22% from the same quarter last year. In Q2, IRLAB Therapeutics AB Class A's net income was $-19.24M. See IRLAB Therapeutics AB Class A’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 57.46M | $ 94.63M | $ 5.68M | $ 61.14M | $ 207.78M | |
| $ -92.35M | $ -92.42M | $ -122.73M | $ -111.23M | $ 168.69M | |
| $ 144.48M | $ 33.45M | $ 58.03M | $ 174.25M | $ 116.11M | |
| Depreciation and Amortization | $ 4.32M | $ 4.58M | $ 4.32M | $ 3.98M | $ 3.47M |
| $ -88.03M | $ -68.07M | $ -173.32M | $ -109.13M | $ 56.05M | |
| $ -92.35M | $ -75.11M | $ -180.76M | $ -113.11M | $ 52.58M | |
| $ -17.66M | $ -8.02M | $ 2.93M | $ -296.00K | $ -795.00K | |
| $ -110.01M | $ -83.13M | $ -177.84M | $ -113.41M | $ 51.78M | |
| $ -110.01M | $ -83.13M | $ -177.84M | $ -114.20M | $ 51.78M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.64 | $ -1.60 | $ -3.43 | $ -2.20 | $ 1.00 |
| Diluted EPS | $ -1.64 | $ -1.60 | $ -3.43 | $ -2.20 | $ 1.00 |
| Weighted Average Shares Outstanding | 67.00M | 51.87M | 51.87M | 51.83M | 51.75M |
| Weighted Average Shares Outstanding (Diluted) | 67.00M | 51.87M | 51.87M | 51.83M | 51.75M |
Currency in SEK